Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015

Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015

Code: GMDHC7199IDB | Published: Dec-2015 | Pages: 639 | Global Markets Direct
Price :
$2,000.00
USD

* Required Fields

$2,000.00

Details

Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015

Summary

Global Markets Directs, Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015, provides an overview of the Type-1 diabetes (Juvenile Diabetes)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type-1 diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note
4SC AG
Adocia
AiCuris GmbH & Co. KG
Amarantus Bioscience Holdings, Inc.
Ambrx, Inc.
AntriaBio, Inc.
Aphios Corporation
Araim Pharmaceuticals Inc.
Argos Therapeutics, Inc.
Artery Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Athersys, Inc.
Axxam SpA
Beta-Cell NV
Biocon Limited
Biodel Inc.
Biogenomics Limited
BioLineRx, Ltd.
BioLingus AG
BioTherapeutics Inc.
Boehringer Ingelheim GmbH
Caladrius Biosciences, Inc.
Carlina Technologies SAS
Cellectis S.A.
Compugen Ltd.
Daewoong Pharmaceutical Co., Ltd.
Dance Biopharm Inc.
Diabetology (Products) Ltd
DiaMedica Inc.
Diasome Pharmaceuticals, Inc.
Dompe Farmaceutici S.p.A.
DoNatur GmbH
Effimune SAS
Eli Lilly and Company
enGene, Inc
EpiVax, Inc.
Evotec AG
F. Hoffmann-La Roche Ltd.
Fate Therapeutics, Inc.
Generex Biotechnology Corporation
GeNeuro SA
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Grifols, S.A.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heptares Therapeutics Limited
Horizon Pharma Plc
Iltoo Pharma
Innopharmax Inc.
IntelliCell BioSciences Inc.
Intrexon Corporation
Islet Sciences, Inc.
Johnson & Johnson
Kadimastem Ltd.
Kamada Ltd.
Kasiak Research Private Limited
Kineta, Inc.
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
Ligand Pharmaceuticals, Inc.
Lonestar Heart, Inc.
MacroGenics, Inc.
Medestea Research & Production S.p.A.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Meridigen Biotech Co., Ltd.
Mertiva AB
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
NatureWise Biotech & Medicals Corporation
NOD Pharmaceuticals, Inc.
Novo Nordisk A/S
Noxxon Pharma AG
Omni Bio Pharmaceutical Inc.
Oramed Pharmaceuticals, Inc.
Orgenesis, Inc.
Paras Biopharmaceuticals Finland Oy
Pathfinder Cell Therapy, Inc.
Pfizer Inc.
PharmaCyte Biotech, Inc.
PharmaIN Corporation
Progen Pharmaceuticals Limited
Prometheon Pharma, LLC
Provid Pharmaceuticals, Inc.
Purzer Pharmaceutical Co., Ltd.
RedHill Biopharma Ltd.
REGiMMUNE Corporation
Sanofi
SEKRIS Biomedical, Inc.
Selecta Biosciences, Inc.
Sevion Therapeutics, Inc.
Strongbridge Biopharma plc
Therapix Biosciences Ltd
Thermalin Diabetes, LLC
Toleranzia AB
Transgene Biotek Limited
Uni-Bio Science Group Ltd.
United Therapeutics Corporation
ViaCyte, Inc.
Visionary Pharmaceuticals, Inc.
XL-protein GmbH
XOMA Corporation
Zensun (Shanghai) Sci & Tech Co., Ltd.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients